Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus

Journal of Clinical Microbiology

Volumn 50, Issue 10, 2012, Pages 3383-3387

  Ludwig, Franziska ^a   Edwards, Becky ^a,c   Lawes, Timothy ^b   Gould, Ian M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b RAIGMORE HOSPITAL   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; DATA BASE; LONGITUDINAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; STORAGE; SYSTEMATIC REVIEW;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; BLOOD; DAPTOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; SPECIMEN HANDLING; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; VANCOMYCIN;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 84866450501     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01158-12     Document Type: Article

References (36)

1. Adam HJ, et al. 2010. Canadian Nosocomial Infection Surveillance Program. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995 to 2006. Antimicrob. Agents Chemother. 54:945-949.
2. Alós JI, GarcíA-Cañas A, GarcíA-Hierro P, Rodríguez-Salvanés F. 2008. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J. Antimicrob. Chemother. 62:773-775.
3. Boyle-Vavra S, Berke SK, Lee JC, Daum RS. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-277. (Pubitemid 30060718)
4. Cui L, et al. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14. (Pubitemid 36098547)
5. Dhand A, Sakoulus G. 2012. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC creep'): implications for therapy. F1000 Med. Rep. 4:4. doi:10.3410/M4-4.
6. Dhawan B, Gadepalli R, Rao C, Kapil A, Sreenivas V. 2010. Decreased susceptibility to vancomycin in meticillin-resistant Staphylococcus aureus: a 5 year study in an Indian tertiary hospital. J. Med. Microbiol. 59:375-376.
7. Edwards B, et al. 2012. Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from northeast Scotland from 2006 to 2010. J. Clin. Microbiol. 50:318-325.
8. Gasch O, et al. 2011. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: secular trends over 19 years at a university hospital. Medicine (Baltimore) 90:319-327.
9. Han JH, Bilker WB, Edelstein PH, Mascitti KB, Lautenbach E. 10 April 2012. Derivation and validation of clinical prediction rules for reduced vancomycin susceptibility in Staphylococcus aureus bacteraemia. Epidemiol. Infect. 2012:1-9. doi:10.1017/S0950268812000295.
10. Hawkey PM. 2009. Low-level glycopeptide resistance in methicillin-resistant Staphylococcus aureus and how to test it. Clin. Microbiol. Infect. 15(Suppl 7):2-9.
11. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. 2011. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int. J. Antimicrob. Agents. 37:219-224.
12. Hiramatsu K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. i:147-155. (Pubitemid 33586048)
13. Ho PL, et al. 2010. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J. Infect. 60:140-145.
14. Holmes RL, Jorgensen JH. 2008. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob. Agents Chemother. 52:757-760. (Pubitemid 351170860)
15. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
16. Jones RN. 2006. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 42(Suppl 1):S13-S24. (Pubitemid 41832061)
17. Kehrmann J, et al. 2011. Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? Eur. J. Clin. Microbiol. Infect. Dis. 30:677-683.
18. Kelley PG, Gao W, Ward PB, Howden BP. 2011. Daptomycin nonsusceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J. Antimicrob. Chemother. 66:1057-1060.
19. Kruzel MC, et al. 2011. Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 49:2272.
20. Lagacé-Wiens P, et al. 2011 Vancomycin and daptomycin MIC creep in Staphylococcus spp. in Canada - analysis of 4642 S. aureus and 497 S. epidermidis isolates from 2007-2010. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17 to 20 September 2011. http://www.icaac.org/.
21. Lubin AS, Snydman DR, Ruthazer R, Bide P, Golan Y. 2011. Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections. Clin. Infect. Dis. 52:997-1002.
22. Moise PA, North D, Steenbergen JN, Sakoulas G. 2009. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 9:617-624.
23. Musta AC, et al. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47:1640-1644.
24. Pitz AM, et al. 2011. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates. J. Clin. Microbiol. 49:269-274.
25. Prakash V, Lewis JS, II, Jorgensen JH. 2008. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob. Agents Chemother. 52:4528.
26. Robert J, Bismuth R, Jarlier V. 2006. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 57:506-510. (Pubitemid 43240204)
27. Sader HS, Rhomberg PR, Jones RN. 2009. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:3162-3165.
28. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Jr, Eliopoulos GM. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585.
29. Steinkraus G, White R, Friedrich L. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794. (Pubitemid 47434257)
30. van Griethuysen A, et al. 2005. Loss of the mecA gene during storage of methicillin-resistant Staphylococcus aureus strains. J. Clin. Microbiol. 43:1361-1365.
31. van Hal SJ, et al. 2011. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J. Antimicrob. Chemother. 66:2284-2287.
32. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54:755-771.
33. Veguilla W, et al. 2008. Two-year study evaluating the potential loss of methicillin resistance in a methicillin-resistant Staphylococcus aureus culture collection. J. Clin. Microbiol. 46:3494-3497.
34. Walraven CJ, et al. 2011. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 66:2386-2392.
35. Wang G, Hindler JF, Ward KW, Bruckner DA. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886. (Pubitemid 44737223)
36. Zhao C, et al. 21 April 2012. Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010). Diagn. Microbiol. Infect. Dis. doi:10.1016/j.diagmicrobio.2012.03.003.